Barings LLC Purchases 810 Shares of Iqvia Holdings Inc (IQV)

Share on StockTwits

Barings LLC raised its position in Iqvia Holdings Inc (NYSE:IQV) by 4.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,092 shares of the medical research company’s stock after purchasing an additional 810 shares during the period. Barings LLC’s holdings in Iqvia were worth $2,746,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Advisory Services Network LLC lifted its holdings in Iqvia by 37.4% in the 4th quarter. Advisory Services Network LLC now owns 5,825 shares of the medical research company’s stock valued at $677,000 after purchasing an additional 1,587 shares in the last quarter. MUFG Securities EMEA plc increased its stake in shares of Iqvia by 2,517.2% during the 4th quarter. MUFG Securities EMEA plc now owns 115,000 shares of the medical research company’s stock valued at $13,360,000 after acquiring an additional 110,606 shares during the last quarter. Sumitomo Mitsui Asset Management Company LTD increased its stake in shares of Iqvia by 12.3% during the 4th quarter. Sumitomo Mitsui Asset Management Company LTD now owns 36,493 shares of the medical research company’s stock valued at $4,239,000 after acquiring an additional 4,006 shares during the last quarter. Sigma Planning Corp acquired a new position in shares of Iqvia during the 1st quarter valued at about $589,000. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp increased its stake in shares of Iqvia by 31.0% during the 4th quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 100,654 shares of the medical research company’s stock valued at $11,693,000 after acquiring an additional 23,800 shares during the last quarter. Institutional investors own 94.19% of the company’s stock.

A number of research analysts have recently commented on the stock. Zacks Investment Research raised shares of Iqvia from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. TheStreet downgraded shares of Iqvia from a “b” rating to a “c+” rating in a research note on Wednesday, May 1st. Wolfe Research assumed coverage on shares of Iqvia in a research note on Tuesday, April 2nd. They set a “market perform” rating for the company. Barclays upped their price objective on shares of Iqvia from $160.00 to $167.00 and gave the company an “overweight” rating in a research note on Monday, March 18th. Finally, Argus upped their price objective on shares of Iqvia from $140.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, February 25th. They noted that the move was a valuation call. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $146.88.

In related news, insider Kevin C. Knightly sold 46,080 shares of the stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $138.06, for a total transaction of $6,361,804.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael J. Evanisko sold 1,193 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $144.95, for a total transaction of $172,925.35. The disclosure for this sale can be found here. In the last three months, insiders have sold 4,187,753 shares of company stock valued at $589,529,674. Corporate insiders own 6.00% of the company’s stock.

IQV opened at $136.38 on Friday. The company has a market cap of $26.90 billion, a P/E ratio of 26.64, a price-to-earnings-growth ratio of 1.63 and a beta of 0.80. Iqvia Holdings Inc has a 1 year low of $97.64 and a 1 year high of $146.10. The company has a debt-to-equity ratio of 1.69, a current ratio of 1.14 and a quick ratio of 1.14.

Iqvia (NYSE:IQV) last posted its earnings results on Wednesday, May 1st. The medical research company reported $1.53 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.41 by $0.12. The firm had revenue of $2.68 billion during the quarter, compared to the consensus estimate of $2.67 billion. Iqvia had a net margin of 2.35% and a return on equity of 15.08%. The company’s revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.34 EPS. On average, analysts expect that Iqvia Holdings Inc will post 5.88 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Barings LLC Purchases 810 Shares of Iqvia Holdings Inc (IQV)” was published by Zolmax and is the property of of Zolmax. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://zolmax.com/investing/barings-llc-purchases-810-shares-of-iqvia-holdings-inc-iqv/3094654.html.

Iqvia Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Story: Trading Stocks – What are percentage gainers?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks Investment Research Upgrades Home Bancshares  to Hold
Zacks Investment Research Upgrades Home Bancshares to Hold
Head-To-Head Analysis: Debenhams  versus ORIENTAL LD CO/ADR
Head-To-Head Analysis: Debenhams versus ORIENTAL LD CO/ADR
Comparing MEI Pharma  & Cambrex
Comparing MEI Pharma & Cambrex
Analyzing Denny’s  and Granite City Food & Brewery
Analyzing Denny’s and Granite City Food & Brewery
Westlake Chemical  Upgraded at ValuEngine
Westlake Chemical Upgraded at ValuEngine
Morgan Stanley Reiterates “$84.00” Price Target for Exxon Mobil
Morgan Stanley Reiterates “$84.00” Price Target for Exxon Mobil


 
© 2006-2019 Zolmax.